Umeclidinium inhalation
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Inhalation powder containing umeclidinium bromide.
Drugs List
Therapeutic Indications
Uses
Chronic obstructive pulmonary disease
Dosage
Adults
One inhalation once daily, at the same time of day.
Maximum daily dose is one inhalation.
Contraindications
Children under 18 years
Breastfeeding
Galactosaemia
Precautions and Warnings
Benign prostatic hyperplasia
Bladder outflow obstruction
Cardiac arrhythmias
Glucose-galactose malabsorption syndrome
Lactose intolerance
Narrow angle glaucoma
Pregnancy
Severe cardiovascular disorder
Severe hepatic impairment
Urinary retention
Ensure patient has a fast acting bronchodilator available
Contains lactose
Check patient is using correct inhaler technique
Discontinue if paradoxical bronchospasm occurs
Advise patient not to use for relief of acute attacks
Advise patient to seek medical advice if treatment is ineffective
Use regularly to maintain freedom from symptoms
Pregnancy and Lactation
Pregnancy
Use umeclidinium with caution during pregnancy.
The manufacturer recommends umeclidinium is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. At the time of writing there is limited human data available. Risks are unknown.
Lactation
Umeclidinium is contraindicated during breastfeeding.
The manufacturer advises discontinuing breastfeeding or discontinuing umeclidinium. It is unknown whether umeclidinium is excreted in human milk. Effects on exposed infants are unknown.
Side Effects
Atrial fibrillation
Blurred vision
Bronchospasm (paradoxical)
Constipation
Cough
Dry mouth
Dysgeusia
Dysuria
Glaucoma
Headache
Hypersensitivity reactions
Increased intra-ocular pressure
Nasopharyngitis
Ocular pain
Pharyngitis
Pruritus
Rash
Rhythm idioventricular
Sinusitis
Supraventricular tachycardia
Tachycardia
Upper respiratory tract infection
Urinary retention
Urinary tract infections
Urticaria
Ventricular extrasystoles
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: December 2020
Reference Sources
Summary of Product Characteristics: Incruse Ellipta 55 micrograms inhalation powder, pre-dispensed. GlaxoSmithKline (Ireland) Limited. Revised September 2019.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.